IP Archives of Cytology and Histopathology Research

Print ISSN: 2581-5725

Online ISSN: 2456-9267

CODEN : IACHCL

IP Archives of Cytology and Histopathology Research (ACHR) open access, peer-reviewed quarterly journal publishing since 2016 and is published under the Khyati Education and Research Foundation (KERF), is registered as a non-profit society (under the society registration act, 1860), Government of India with the vision of various accredited vocational courses in healthcare, education, paramedical, yoga, publication, teaching and research activity, with the aim of faster and better dissemination of knowledge, we will be publishing the article more...

  • Article highlights
  • Article tables
  • Article images

Article statistics

Viewed: 456

PDF Downloaded: 231


Get Permission Bhadauria, Singh, and Patra: Rare case study of Covid agitation: The novel sinner causes a diagnostic dilemma


Introduction

In December 2019, Wuhan, witnessed an outbreak of pneumonia by an unknown etiological agent. On 7th of January 2020, a group of Chinese scientists identified this virus as a previously unknown type of Coronavirus and named it 2019-nCoV (for 2019 novel coronavirus) 1, 2 and soon, this COVID-19 virus had spread to many other countries having frequent visitors from China.3 World Health Organization (WHO) officially announced this novel coronavirus disease on 11th February 2020 as Coronavirus Disease 19 (COVID-19).3 International Committee on Taxonomy of Viruses suggested the name SARS-CoV-2 for the virus that causes COVID-19.4 01 Month later on 11th March 2020, World Health Organization declared this outbreak a pandemic. 5 The situation has worsened in leaps and bounds since then and 2021 has been hit worst by this.

The primary symptoms of COVID-19 include fever, dry cough, and fatigue.6 However, some patients diagnosed with COVID-19 have not shown these typical symptoms at the time of diagnosis, instead, they exhibited only neurological symptoms at the prodrome. These symptoms were non-specific manifestations like headache, anosmia, diarrhea, malaise, and specific complaints like unstable walking, disorientation due to cerebral hemorrhage, cerebral infarction; as well as other neurological diseases.7 Even to date, we have scarce literature on COVID-19 symptoms associated with the nervous system.

COVID-19 has killed millions across the world and has affected every nation, every individual on this planet, directly or indirectly, by causing a spectrum of disorders oscillating from no symptoms to death and indirectly by resulting in sickness or loss of a family member or socioeconomic turbulence due to restricted services, movement of people and goods, inflation, stock market collapse, declining GDP and grief and increasing mental stress.8 Initially only respiratory symptoms were reported due to SARS-CoV-2 infection but thereafter several non-respiratory features have been observed, including neurological deficits. Contemporary literature has shown that neurological symptoms were found in 84% of the patients that entered the intensive care unit without sedation and neuromuscular blockers. They expressed CNS dysfunction symptoms such as agitation (69%) and confusion (65%). 9 A systematic review showed that 23% of the patients also had complications of encephalopathy or encephalitis. 10 These results have indicated the possibility of central nervous system involvement in the course of COVID-19 disease, with the presence of SARS-CoV-2 neurotropism. 11 Several other reports also suggest that various neurologic sequelae may arise in association with respiratory coronavirus syndromes, including encephalitis, seizures, encephalopathy, Guillain-Barre syndrome (GBS), anosmia, enteropathy, neuromuscular disorders, and demyelinating diseases. 10, 11, 12, 13 Similarly, the neurotropism of other types of human coronaviruses (including HCoV-229E, HCoV-OC43, HCoVHKU1, and HCoV-NL63) and their possible association with neurologic diseases such as multiple sclerosis (MS) have been debated in earlier studies. 14, 15

A very recent review has found that myalgia, anosmia, headache, cerebrovascular disease, and encephalopathy are amongst the most common neurological manifestations associated with SARS-CoV-2 infection. 16 Neurological features such as weakness, pain, and numbness are reported readily as they are easily noticed by the patients. Direct neural invasion, neuroinflammation, systemic pro-inflammatory state, and hypoxia have all been suggested to mediate the neurological dysfunction in COVID-19. 17 Thus, indicating a direct pathophysiological basis to the neurological features.

SARS-CoV-2 virus can cross the blood-brain barrier, most probably, the virus travels to the brain by a hematogenous route or trans-neuronally to the brain via the olfactory system, across cribriform plate.18 Angiotensin-converting enzyme-2 (ACE-2) receptor's role in virus binding is well known and their presence on endothelial cells of cerebral vasculature act as entry points for the virus 19. In an autopsy-based study, it was demonstrated that the SARS-CoV-2 virus is present in neural and capillary endothelial cells of the frontal lobe of the brain. Neurons or microglia did not have angiotensin-converting enzyme two receptors.20 Comorbidities, like diabetes and hypertension, enhance the angiotensin-converting enzyme 2 receptor expression in the brain and in turn, increase neuro-tropism of the SARS-CoV-2 virus. 21 The SARS-CoV-2 virus epitopes bear a structural resemblance to several human proteins. Hence, molecular mimicry between virus epitope and myelin basic protein results in auto-immune post-infectious demyelinating syndromes. 22 Dysregulation of the angiotensin-converting enzyme-2 receptor also contributes to the pathogenesis of experimental autoimmune encephalomyelitis. 23, 24 Spike surface glycoprotein plays a crucial role in immunopathology. Delirium is often associated with systemic inflammation and prolonged hypoxia. Middle-aged and older adults with severe disease are more likely to be affected.25 Altered sensorium, in COVID-19, is associated with an increased risk of death. 26 Xiang and co-workers, in Beijing, China, claimed to isolate the first SARS-CoV-2 virus in cerebrospinal fluid (CSF).27 In only a handful of patients, the SARS-CoV-2 virus in CSF has been isolated. In a case of COVID-19 associated encephalitis, MRI revealed the involvement of brain parenchyma. Patients also presented with corticosteroid-responsive encephalopathy, acute disseminated encephalomyelitis, and immune-mediated acute hemorrhagic necrotizing encephalopathy. 28, 29, 30, 31

Severe COVID-19 is characterized by profound coagulopathy. In patients of severe COVID-19, coagulopathies are important detrimental factors that are invariably associated with poorer outcomes. The hallmark coagulopathy abnormalities in COVID-19 are raised prothrombin time (PT), raised D-dimer level, and mild thrombocytopenia, but without hypofibrinogenemia. DIC is characterized by thrombocytopenia, prolonged PT, and markedly elevated D-dimer. 32, 33 Coagulopathies in COVID-19 predispose to stroke and other prothrombotic events. 34, 35, 36 Severe COVID-19 is also characterized by markedly elevated levels of pro-inflammatory cytokines, lymphopenia, increased number of neutrophils collectively termed as “cytokine storm”, approximately, 5% of COVID-19 patients develop acute respiratory distress syndrome (ARDS), septic shock, and/or multiple organ dysfunctions (MODS). A cytokine storm is held responsible for the pathogenesis of all the complications of severe COVID-19. 37, 38 The SARS-CoV-2 virus infection can trigger hemophagocytic lympho-histiocytosis (HLH), which is a rare hyperinflammatory condition characterized by a severe hyper-cytokinaemia with multiorgan failure. 39, 40 Recently even “bradykinin storm” has been proposed as a phenomenon well observed in severe COVID-19 41.

Thus, the author here wants to highlight two interesting cases which presented with non-specific neurological symptoms and turned out to be primarily COVID-19 positive with meningo-enchephalitis.

Case Study

Case 1

A 19 years old male was brought by his colleagues to the Emergency Room in agitated condition, not responding to verbal commands for the past few hours and having high-grade fever for past few hours. There was a history of headache and insomnia for past 02 days. No other relevant history and symptoms. No known comorbidities. There was no history of recent travel or trauma. No signs and symptoms of upper and lower respiratory symptoms.

On initial examination vital parameters were

Blood Pressure – 120/70 mmHg, Pulse Rate – 110/min, Temperature – 104 Degree Fahrenheit, SpO2 – 98% on room air.

Systemic examination revealed

Respiratory system – Bilateral normal vesicular breath sounds, no wheeze / crepitations heard.

Cardiovascular system – S1S2 heard normally, no murmurs / splits heard.

Per-abdominal system – Soft, non-tender, no organomegaly, bowel sounds heard normally.

Neurological system – Pupils were bilaterally reacting to light equally, moving all four limbs, agitated and not responding to verbal commands. Responds to pain. No apparent motor deficit.

Case 2

A 46 years old female brought by her relatives to the Emergency Room in confused and delirious condition, not responding to verbal communication from past few hours and having low grade fever since last 01 day. There was history of myalgia, headache and insomnia from past 02 days. K/c/o HTN and arthritis, on medication. No other relevant history and symptoms. There was no history of recent travel or trauma. No signs and symptoms of upper and lower respiratory symptoms.

On initial examination vital parameters were

Blood Pressure – 130/80 mmHg, Pulse Rate – 100/min, Temperature – 101 Degree Fahrenheit, SpO2 – 97% on room air.

Systemic examination revealed

Respiratory system – Bilateral normal vesicular breath sounds, no wheeze / crepitations heard.

Cardiovascular system – S1S2 heard normally, no murmurs / splits heard.

Per-abdominal system – Soft, non-tender, no organomegaly, bowel sounds heard normally.

Neurological system – Pupils were bilaterally reacting to light equally, moving all four limbs, delirious and not responding to verbal commands. Responds to pain. No apparent motor deficit.

Diagnosis

In both cases, a diagnosis of COVID Associated MENINGO-ENCEPHALITIS was made.

Management

Patients were managed with steroids and a single dose of Inj. Tocilizumab, to which they responded well and became asymptomatic within 02 weeks of intensive care at ICU and were discharged to home with directions to follow National guidelines regarding Home Quarantine for the period of convalescence.

Discussion

The above cases clearly demonstrate the levels of subtleness in the symptomatic presentations of neurological involvement of COVID-19. Although the main target of organ damage by SARS-CoV-2 has been the respiratory system, patients have also experienced neurological problems ranging from the mild manifestations (headaches and dizziness) to life-threatening complications (cerebrovascular disorders and encephalitis). Current literature shows that agitation (69%) was the common complaint found in COVID-19 patients receiving treatment in the Intensive Care Unit (ICU). 42 In our cases, fever, headache, insomnia with agitation and confusion were the primary symptoms. Recent publications have also proved this atypical presentation of COVID-19. Based on current studies, the common symptoms found in most of the common causes of acute viral encephalitis patients are disorientation or confusion (72.72%), decreased consciousness (54.54%), and seizures (27.27%). These symptoms indicate damages in the central nervous system, especially the cerebral cortex, typically found in acute encephalitis. In COVID-19 associated encephalitis, the manifestations of seizures and headaches are found in 27.27% and 30.3% of the cases, while HSV encephalitis seizures are found in 56% of the cases and headaches in 83% of the cases. 43 Abnormal behaviour that is characteristically found in HSV is rarely found in COVID-19 associated encephalitis. The clinical appearance of COVID-19 associated encephalitis is parallel to MERS-CoV-2 associated encephalitis, like symptoms of upper respiratory tract infection (fever, cough, fatigue, etc.), a decrease in mental status and rapid respiratory failure. 43 Meningeal irritation sign has not been classically found in this association, which suggests that the pathological process is more dominant in the cortex than in the meninges.

Table 1

Investigations

S.No.

Investigation

Reports Case-1

Reports Case-2

Haematology

1.

Hb

14 gm%

11.4 gm%

2.

TLC

9100/ul

8600/ul

3.

DLC

Neutrophils- 89%, Lymphocytes- 08%, Monocytes- 02%, Eosinophils- 01%, Basophils- 00%

Neutrophils- 71%, Lymphocytes- 18%, Monocytes- 03%, Eosinophils- 08%, Basophils- 00%

4.

PT Patient

16

15

5.

PT Control

13

13

6.

INR

1.1

1.1

7.

PTTK Patient

35

--

8.

PTTK Control

32

--

9.

MP Paracheck

Negative

Negative

10.

PBS for MP

No Malarial Parasite seen

No Malarial Parasite seen

11.

Dengue IgG/IgM/NS1Ag

Negative

Negative

Serology

1.

Ferritin (Vidas)

156.91 ng/ml

169.23 ng/ml

2.

Procalcitonin (Vidas)

0.05 ng/ml

0.09 ng/ml

3.

D-Dimer (Vidas)

2913.87 ng/ml of FEU

2801.66 ng/ml of FEU

4.

CRP

Negative

Raised

Biochemistry

1.

Calcium

Albumin Calcium – 3.8 gm/dl; Calcium 2 – 7.9 mg/dl

2.

Blood Sugar

Fasting – 102 mg/dl; Post Prandial – 148 mg/dl; Random Blood Sugar – 118 mg/dl

Random Blood Sugar – 126 mg/dl Fasting – 92 mg/dl PP – 168 mg/dl

3.

Urea

18 mg/dl

32 mg/dl

4.

Creatinine

0.6 mg/dl

0.8 mg/dl

5.

Uric Acid

4.8 mg/dl

6.2 mg/dl

6.

Albumin

3.8 gm/dl

3.7 gm/dl

7.

Proteins

6.5 gm/dl

5.7 gm/dl

8.

Globulin

2.7 gm/dl

2.0 gm/dl

9.

AG Ratio

1.4

1.9

10.

Bilirubin

Total – 1.4 mg/dl; Direct – 0.3 mg/dl

T – 1.0 mg/dl; Direct – 0.3 mg/dl

11.

SGOT/AST

83 IU/L

100 IU/L

12.

SGPT/ALT

43 IU/L

56 IU/L

13.

ALP

108 IU/L

70 IU/L

14.

LDH

515 IU/L

300 IU/L

15.

Sodium

135 meq/dl

136 meq/dl

16.

Potassium

3.0 meq/dl

3.4 meq/dl

CSF Cytology

1.

Appearance

Clear

Clear

2.

Volume

02 ml

01 ml

3.

Reaction

Alkaline

Alkaline

4.

RBCs

Nil

Nil

5.

WBCs

7/cmm

10/cmm

6.

Predominant Cells

Lymphocytes

Lymphocytes

CSF Biochemistry

1.

CSF Glucose

79 mg/dl

82 mg/dl

2.

CSF Protein

62.2 mg/dl

66 mg/dl

3.

CSF Globulin

Not Increased

Not raised

4.

CSF ADA

2.2 IU/L

2.8 IU/L

CSF Microbiology

1.

CSF Culture

No Growth seen after 48 hours

No Growth seen after 48 hours

2.

CSF Gram Stain

Negative

Negative

3.

CSF ZN Stain

Negative

Negative

4.

CSF India Ink Preparation

Negative

Negative

Chest X-Ray

Normal

Normal

NCCT Chest and Brain

Normal

Normal

MRI Brain

Hyperintense focal areas in left posterior-parietal lobe and parieto-occipital lobe, wall of frontal parietal lobe, cortical and sub-cortical areas. Meningeal enhancement seen. Suggestive of Meningoenchephalitis.

Non confluent multifocal white matter hyper intense lesions seen with signal abnormalities located in medial temporal lobe. Occasional isolated microhemorrhages noted along with meningeal enhancement. Indicative of Meningoenchephalitis

COVID19 Testing

CBNAAT Positive

CBNAAT Positive

HSV PCR

Negative

Negative

This also indicates that the involvement of meninges in COVID-19-associated encephalitis is less common than HSV 44. Same has been found in our cases. Though largely COVID-19 patients have shown a normal magnetic resonance imaging (MRI) images, the most common radio-pathological finding in most of the current studies has been diffuse hyper-intensity of T2 / Fluid attenuated inversion recovery (FLAIR), with location most frequently in white matter which was the chief finding in our cases too. A case series of three cases of middle east reported respiratory syndrome coronavirus (MERS-CoV) patients that evaluation by MRI showed hyper-intense lesions on T2, spread widely and bilaterally in white matter and subcortical areas, frontal lobes, temporal, parietal, and basal ganglia, as well as the corpus callosum. 45 Thus, the neuroimaging findings suggest possible similarities in the pathological mechanism of the central nervous system involvement in SARS-CoV- 2, SARS-CoV, and MERS-CoV, which was the common finding in our cases also. The CSF analysis of our cases showed slightly raised number of white blood cells with lymphocyte predominance, and raised levels of CSF proteins, which has been the finding in many contemporary studies and case series, showing increase in protein levels (42.42%), white blood cells (WBCs) (27.27%), and lymphocytes (24.24%). In addition, most of the case series have also reported that the cerebrospinal fluid (CSF) and polymerase chain reaction (PCR) examination with a negative result for SARS-CoV-2, due to the direct invasion of the virus into white matter. 44, 45, 46, 47, 48, 49 Our cases were not subjected for CSF SARS-CoV-2 analysis as enough evidence has been published directly associating SARS-CoV-2 with Meningo-enchephalitis as CSF tested positive for SARS-CoV-2 RNA also there is evidence of associated intracerebral micro-hemorrhages of medial temporal lobe as seen in our case. 50

Conclusion

Patients with atypical neurological presentations during the COVID pandemic need a strong suspicion towards COVID-associated CNS symptoms. CNS infection by SARS-CoV-2 has been seen to result in severe COVID disease if not managed aggressively. MRI brain forms a mainstay modality in these atypical CNS cases. All flu-like cases even with atypical presentations need to be subjected to COVID-19 testing.

Acknowledgment

Dr. Subin Philip (Medicine Specialist), Dr. NS Beniwal (Dermatologist), Dr. S Kishore (General Practitioner).

Conflict of Interest

The authors declare that there is no conflict of interest.

Source of Funding

None.

References

1 

D A Schwartz A L Graham Potential maternal and infant outcomes from coronavirus 2019-nCoV (SARS-CoV-2) infecting pregnant women: lessons from SARS, MERS, and other human coronavirus infectionsViruses202012219410.3390/v12020194

2 

K Ma T Chen M F Han W Guo Q Ning Management and clinical thinking of Coronavirus Disease 2019Zhonghua Gan Zang Bing Za Zhi201928E00210.3760/cma.j.issn.1007-3418.2020.0002

3 

WHO. Disease outbreak news (DONs). World Health Organization; 2020, November 11. [retrieved Nov 11, 2020 from]. https://www.who.int/emergencies/disease-outbreak-news

4 

A E Gorbalenya Severe acute respiratory syndrome-related coronavirus: the species and its viruses - a statement of the coronavirus Study GroupbioR xiv202010.1038/s41564-020-0695-z

5 

WHO. Coronavirus disease (COVID-19). World Health Organization; 2020, March 27. [retrieved Mar 27, 2020 from]https://www.who.int/health-topics/coronavirus

6 

C Huang Y Wang X Li L Ren J Zhao Y Hu Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaLancet20203951022349750610.1016/S0140-6736(20)30183-5

7 

L Mao H Jin M Wang Y Hu S Chen Q He Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, ChinaJAMA Neurol20207766837010.1001/jamaneurol.2020.1127

8 

K Meier T Glatz M C Guijt M Piccininni M Van Der Meulen K Atmar Public perspectives on protective measures during the COVID-19 pandemic in the Netherlands, Germany and Italy: A survey studyPLOS ONE2020158e023691710.1371/journal.pone.0236917

9 

J Helms S Kremer H Merdji R Clere-Jehl M Schenck C Kummerlen Neurologic features in severe SARS-CoV-2 infectionN Engl J Med20203822322687010.1056/NEJMc2008597

10 

M Ghannam Q Alshaer M Al-Chalabi L Zakarna J Robertson G Manousakis Neurological involvement of coronavirus disease 2019: a systematic reviewJ Neurol20202671131355310.1007/s00415-020-09990-2

11 

A M Baig A Khaleeq U Ali H Syeda Evidence of the COVID-19 virus targeting the CNS: tissue distribution, Host-Virus Interaction, and Proposed Neurotropic MechanismsACS Chem Neurosci20201179958

12 

L K Tsai S T Hsieh C C Chao Y C Chen Y H Lin S C Chang Neuromuscular disorders in severe acute respiratory syndromeArch Neurol2004611116697310.1001/archneur.61.11.1669

13 

K K Lau W C Yu C M Chu S T Lau B Sheng K Y Yuen Possible central nervous system infection by SARS coronavirusEmerg Infect Dis2004102342410.3201/eid1002.030638

14 

A Salmi B Ziola T Hovi M Reunanen Antibodies to coronaviruses OC43 and 229E in multiple sclerosis patientsNeurology1982323292510.1212/wnl.32.3.292

15 

Y Li H Li R Fan B Wen J Zhang X Cao Coronavirus infections in the central nervous system and respiratory tract show distinct features in hospitalized childrenIntervirology2016593163910.1159/000453066

16 

R P Munhoz J L Pedroso F A Nascimento S M Almeida OGP Barsottini FEC Cardoso Neurological complications in patients with SARS-CoV-2 infection: a systematicreviewArq Neuro Psiquiatr202078529030010.1590/0004-282x20200051

17 

H Yavarpour-Bali M Ghasemi-Kasman Update on neurological manifestations of COVID-19Life Sci200925711806310.1016/j.lfs.2020.118063

18 

S Natoli V Oliveira P Calabresi L F Maia A Pisani Does SARS-Cov-2invade the brain? Translational lessons from animal modelsEur J Neurol2020279176473

19 

M Y Li L Li Y Zhang X S Wang Expression of the SARS-CoV-2 cellreceptor gene ACE2 in a wide variety of human tissuesInfect Dis Pover2020914510.1186/s40249-020-00662-x

20 

A Paniz-Mondolfi C Bryce Z Grimes R E Gordon J Reidy J Lednicky Central nervous system involvement by severe acute respiratory syndromecoronavirus -2 (SARS-CoV-2)J Med Virol202092769970210.1002/jmv.25915

21 

V G Puelles M Lütgehetmann M T Lindenmeyer J P Sperhake M N Wong L Allweiss Multiorgan and renal tropism of SARS-CoV-2N Engl J Med J Med20203836590210.1056/NEJMc2011400

22 

J Lyons-Weiler Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunityJ Transl Autoimmun2020310005110.1016/j.jtauto.2020.100051

23 

C A Pérez Looking ahead: the risk of neurologic complications due toCOVID-19Neurol Clin Pract2020104371410.1212/CPJ.0000000000000836

24 

A C Guidon A A Amato COVID-19 and neuromuscular disordersNeurology202094229596910.1212/WNL.0000000000009566

25 

L Mao H Jin M Wang Y Hu S Chen Q He Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, ChinaJAMA Neurol20207766839010.1001/jamaneurol.2020.1127

26 

T Chen D Wu H Chen W Yan D Yang G Chen Clinical characteristics of 113 deceased patients with coronavirus disease 2019:retrospective studyBMJ2020368109110.1136/bmj.m1091

27 

P Xiang X M Xu L L Gao H Z Wang H F Xiong R H Li First case of 2019 novel coronavirus disease with EncephalitisChina Xiv T2020

28 

N Poyiadji G Shahin D Noujaim M Stone S Patel B Griffith COVID-19-associated Acute hemorrhagic Necrotizing encephalopathy: CT and MRI featuresRadiology20202962E1192010.1148/radiol.2020201187

29 

J R Sachs K W Gibbs D E Swor A P Sweeney D W Williams J H Burdette COVID-19-associated leukoencephalopathyRadiology20202963E184510.1148/radiol.2020201753

30 

T Zhang M B Rodricks E Hirsh COVID-19-associated acute disseminated encephalomyelitis - A case reportmedRxiv202010.1007/s12028-020-01119-7

31 

A Pilotto S Odolini S Masciocchi A Comelli I Volongh S Gazzina Steroid-responsive severe encephalopathy in SARS-CoV-2 infectionAnn Neurol2020882423710.1002/ana.25783

32 

S R Mucha S Dugar K Mccrae D E Joseph J Bartholomew G L Sacha Coagulopathy in COVID-19: manifestations and managementCleve Clin J Med2020878461810.3949/ccjm.87a.ccc024

33 

D Lillicrap Disseminated intravascular coagulation in patients with 2019-nCoV pneumoniaJ Thromb Haemost2020184786710.1111/jth.14781

34 

A Kollias K G Kyriakoulis E Dimakakos G Poulakou G S Stergiou K Syrigos Thromboembolic risk and anticoagulant therapy in COVID-19 patients:emerging evidence and call for actionBr J Haematol20201895846710.1111/bjh.16727

35 

B Bikdeli M V Madhavan D Jimenez T Chuich I Dreyfus E Driggin COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-upJ Am Coll Cardiol2020752329507310.1016/j.jacc.2020.04.031

36 

D C Hess W Eldahshan E Rutkowski COVID-19-related strokeTransl Stroke Res2020113322510.1007/s12975-020-00818-9

37 

Y Feng Y Ling T Bai Y Xie J Huang J Li COVID-19 withDifferent severity: A multi-center study of clinical featuresAm J Respir Crit Care Med2020201111380810.1164/rccm.202002-0445OC

38 

F Yang S Shi J Zhu J Shi K Dai X Chen Analysis of 92 deceased patients with COVID-19J Med Virol202092112511510.1002/jmv.25891

39 

D Mcgonagle K Sharif A O’regan C Bridgewood The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like diseaseAutoimmun Rev202019610253710.1016/j.autrev.2020.102537

40 

F Radmanesh A Rodriguez-Pla M D Pincus J D Burns Severe cerebral involvement in adult-onset hemophagocytic lymphohistiocytosisJ Clin Neurosci202076236710.1016/j.jocn.2020.04.054

41 

National Health Service (NHS) Medically Unexplained Symptoms. [accessed Sep 13, 2020]2020https://www.nhs.uk/conditions/medically-unexplained-symptoms/

42 

J Helms S Kremer H Merdji R Clere-Jehl M Schenck C Kummerlen Neurologic features in severe SARS-CoV-2 infectionN Engl J Med20203822322687010.1056/NEJMc2008597

43 

U Sili A Kaya A Mert Herpes simplex virus encephalitis: clinical manifestations, diagnosis and outcome in 106 adult patientsJ Clin Virol2014602112810.1016/j.jcv.2014.03.010

44 

L Mao H Jin M Wang Y Hu S Chen Q He Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, ChinaJAMA Neurol20207766839010.1001/jamaneurol.2020.1127

45 

Y M Arabi A Harthi J Hussein A Bouchama S Johani A H Hajeer Severe neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS-CoV)Infection201543449550110.1007/s15010-015-0720-y

46 

Y M Siahaan V Puspitasari A R Pangestu Covid-19-associated Encephalitis: systematic Review Of Case Reportsfindings On Cytokine-immune-mediated Inflammation As An Underlying Mechanism202010.21203/rs.3.rs-65579/v1

47 

Y R Guo Q D Cao Z S Hong Y Y Tan S D Chen H J Jin The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-an update on the statusMil Med Res2020711110.1186/s40779-020-00240-0

48 

Z Xu L Shi Y Wang J Zhang L Huang C Zhang H Liu Pathological findings of COVID-19 associated with acute respiratory distress syndromeLancet Respir Med202084420210.1016/S2213-2600(20)30076-X

49 

I E Efe O U Aydin A Alabulut O Celik K Aydin COVID-19-Associated Encephalitis Mimicking Glial TumorWorld Neurosurg202014046810.1016/j.wneu.2020.05.194

50 

S Kremer F Lersy J De Sèze J C Ferré A Maamar B Carsin-Nicol Brain MRI findings in severe COVID-19: a retrospective observational studyRadiology202029722425110.1148/radiol.2020202222



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Article type

Case Report


Article page

60-66


Authors Details

Gyanendra Singh Bhadauria, Swarnima Singh, M K Patra


Article History

Received : 02-11-2021

Accepted : 29-12-2021


Article Metrics


View Article As

 


Downlaod Files